Introduction
On January 7, 2025 [9], the FDA released draft guidance titled “Artificial Intelligence-Enabled Device Software Functions: Lifecycle Management and Marketing Submission Recommendations.” This document provides a comprehensive framework to support the design, development [1] [2] [3] [4] [5] [6] [7] [8] [9], testing [2] [5] [6] [7] [8] [9], and marketing of AI-enabled medical devices [1] [6] [7], ensuring their safety and effectiveness [1] [2] [5] [6] [7] [8] throughout their Total Product Lifecycle (TPLC).
Description
This guidance integrates Good Machine Learning Practice (GMLP) principles to ensure the safety, effectiveness, and reliability of AI-enabled medical devices [1]. Key recommendations include a detailed device description that clarifies functionality and intended use, requiring manufacturers to provide information on device inputs, outputs [2] [7], intended users [2] [7] [9], use environments [7], and workflows [7]. The guidance emphasizes the importance of user-friendly interfaces and comprehensive labeling to facilitate clear communication of device functionality and performance for healthcare professionals and patients.
A comprehensive risk management approach is emphasized throughout the device’s lifecycle [8], addressing potential hazards and user errors [7]. Manufacturers are encouraged to develop robust risk assessment plans that prioritize safety and include ongoing post-market performance monitoring to identify and address any changes in device reliability.
Data management practices are critical, with manufacturers expected to ensure data diversity, quality [7], and quantity to mitigate bias and enhance model accuracy [7]. The guidance highlights the need for transparent AI model design, requiring documentation of model architecture, training methods [2] [7], performance metrics [1] [2] [3] [5] [6] [7] [8] [9], and feature selection processes [7].
Validation for AI-enabled devices involves rigorous studies [2], including human factors and usability testing [7], to confirm performance in real-world scenarios [7]. The draft also proposes a performance monitoring plan as a risk mitigation strategy [3], emphasizing the importance of conveying relevant information to users [3], including the use of model cards that detail AI model characteristics.
Cybersecurity is underscored as a significant concern, particularly for devices classified as “cyber devices.” Manufacturers must implement robust cybersecurity measures to protect against risks such as data poisoning and model evasion, ensuring device integrity [7]. Transparency in public submission summaries is crucial [2], necessitating clear statements about AI usage [2], model descriptions [2] [7] [9], and performance metrics [2] [3] [7] [9].
The guidance promotes early and ongoing engagement with sponsors to effectively utilize these recommendations during planning, development [1] [2] [3] [4] [5] [6] [7] [8] [9], testing [2] [5] [6] [7] [8] [9], and monitoring phases [6] [8]. It encourages manufacturers to evaluate device performance across diverse demographic groups to ensure equitable outcomes and to tailor testing protocols for AI-specific cybersecurity risks.
To assist stakeholders, the FDA will conduct a webinar on February 18, 2025 [4], providing an overview of the guidance and encouraging engagement regarding lifecycle considerations for AI-enabled device software functions. Interested parties can access the draft guidance electronically through various FDA resources or request a copy via email [3]. Public comments on the draft guidance are requested by April 7, 2025 [5] [8], with specific feedback sought on its alignment with the AI lifecycle [8], adequacy of recommendations for emerging technologies like generative AI [8], performance monitoring approaches [2] [3] [5] [6] [8] [9], and information dissemination about AI-enabled devices to users [8].
Conclusion
The FDA’s draft guidance on AI-enabled medical devices is poised to significantly impact the industry by establishing a robust framework for lifecycle management. By emphasizing safety, transparency [1] [2] [3] [5] [6] [7] [8] [9], and cybersecurity [2] [7] [9], the guidance aims to foster innovation while ensuring equitable and reliable outcomes for diverse patient populations. The call for public engagement and feedback further underscores the FDA’s commitment to refining these recommendations to address emerging technological challenges effectively.
References
[1] https://www.medtechdive.com/news/fda-device-ai-draft-guidance/736682/
[2] https://www.jdsupra.com/legalnews/fda-releases-draft-guidance-on-3585261/
[3] https://www.govinfo.gov/content/pkg/FR-2025-01-07/html/2024-31543.htm
[4] https://www.ansi.org/standards-news/all-news/2025/01/1-7-25-fda-seeks-comments-on-draft-guidance-for-ai-enabled-medical-device-software-lifecycle
[5] https://24x7mag.com/standards/fda-updates/fda-issues-draft-guidance-for-ai-enabled-devices/
[6] https://www.healthcareitnews.com/news/fda-offers-new-draft-guidance-developers-ai-enabled-medical-devices
[7] https://www.digitalhealthglobal.com/fda-issues-draft-guidance-for-ai-enabled-medical-devices-key-recommendations-and-updates/
[8] https://www.prnewswire.com/news-releases/fda-issues-comprehensive-draft-guidance-for-developers-of-artificial-intelligence-enabled-medical-devices-302343044.html
[9] https://www.kslaw.com/news-and-insights/fda-releases-draft-guidance-on-submission-recommendations-for-ai-enabled-device-software-functions
